Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data
نویسندگان
چکیده
BACKGROUND Little is known on the cost-effectiveness of novel regimens for hepatitis C virus (HCV) compared with standard-of-care with pegylated interferon (pegIFN) and ribavirin (RBV) therapy in developing countries. We evaluated cost-effectiveness of sofosbuvir/ledipasvir for 12 weeks compared with a 48-week pegIFN-RBV regimen in Chinese patients with genotype 1b HCV infection by economic regions. METHODS A decision analytic Markov model was developed to estimate quality-adjusted-life-years, lifetime cost of HCV infection and incremental cost-effectiveness ratios (ICERs). SVR rates and direct medical costs were obtained from real-world data. Parameter uncertainty was assessed by one-way and probabilistic sensitivity analyses. Threshold analysis was conducted to estimate the price which can make the regimen cost-effective and affordable. RESULTS Sofosbuvir/ledipasvir was cost-effective in treatment-experienced patients with an ICER of US$21,612. It varied by economic regions. The probability of cost-effectiveness was 18% and 47% for treatment-naive and experienced patients, and it ranged from 15% in treatment-naïve patients in Central-China to 64% in treatment-experienced patients in Eastern-China. The price of 12-week sofosbuvir/ledipasvir treatment needs to be reduced by at least 81% to US$18,185 to make the regimen cost-effective in all patients at WTP of one time GDP per capita. The price has to be US$105 to make the regimen affordable in average patients in China. CONCLUSION Sofosbuvir/ledipasvir regimen is not cost-effective in most Chinese patients with genotype 1b HCV infection. The results vary by economic regions. Drug price of sofosbuvir/ledipasvir needs to be substantially reduced when entering the market in China to ensure the widest accessibility.
منابع مشابه
Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
DAA: direct antiviral agents HCV: hepatitis C virus LP: lichen planus INTRODUCTION Lichen planus (LP) is a chronic inflammatory disease affecting the skin and mucosa of squamous cell origin and has a significantly higher prevalence in patients infected with the hepatitis C virus (HCV). Although ribavirin-based treatments frequently show exacerbations of these lesions, currently there is little ...
متن کاملCost-effectiveness of novel regimens for the treatment of hepatitis C virus.
BACKGROUND New regimens for hepatitis C virus (HCV) have shorter treatment durations and increased rates of sustained virologic response compared with existing therapies but are extremely expensive. OBJECTIVE To evaluate the cost-effectiveness of these treatments under different assumptions about their price and efficacy. DESIGN Discrete-event simulation. DATA SOURCES Published literature...
متن کاملLedipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection.
Ledipasvir/sofosbuvir (Harvoni): improving options for hepatitis C virus infection.
متن کاملAssay and Dissolution Methods Development and Validation for Simultaneous Determination of Sofosbuvir and Ledipasvir by RP-HPLC Method in Tablet Dosage Forms
Globally, between 130-150 millions of people have chronic hepatitis C infection. A significant number of those who are chronically infected will develop liver cirrhosis or liver cancer. Approximately 700 000 people die each year from hepatitis C-related liver diseases [1]. Egypt has the largest epidemic of HCV in the world according to the released Egyptian Demographic Health Survey [EDHS] and ...
متن کاملCost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
BACKGROUND Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE To evaluate the cost-effectiveness and budget impa...
متن کامل